Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
World game at war: why some European nations have threatened a World Cup boycott 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
